EYEPOINT PHARMACEUTICALS INC (EYPT) Stock Price, Forecast & Analysis
USA - NASDAQ:EYPT - US30233G2093 - Common Stock
EYPT Key Statistics, Chart & Performance
The current stock price of EYPT is 11.99 USD. In the past month the price increased by 2.22%. In the past year, price increased by 30.75%.
EYPT Latest News, Press Relases and Analysis
EYPT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 46.28 | 963.29B | ||
| JNJ | JOHNSON & JOHNSON | 18.73 | 468.16B | ||
| MRK | MERCK & CO. INC. | 10.38 | 228.42B | ||
| PFE | PFIZER INC | 8.08 | 147.09B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.48 | 99.90B | ||
| ZTS | ZOETIS INC | 19.12 | 53.74B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.63 | 23.09B | ||
| VTRS | VIATRIS INC | 4.73 | 12.84B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.97 | 10.95B | ||
| CORT | CORCEPT THERAPEUTICS INC | 89.08 | 8.26B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.03B | ||
| LGND | LIGAND PHARMACEUTICALS | 28.2 | 4.03B |
Related stock screener links
About EYPT
Company Profile
EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. The company is headquartered in Watertown, Massachusetts and currently employs 165 full-time employees. The company went IPO on 2005-01-27. The firm is focused on developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E. DURAVYU is presently in Phase 3 global, pivotal clinical trials for wet age-related macular degeneration (wet AMD). Additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The Company’s other products include YUTIQ and DEXYCU.
Company Info
EYEPOINT PHARMACEUTICALS INC
480 Pleasant Street, Suite C400
Watertown MASSACHUSETTS 02472 US
CEO: Nancy Lurker
Employees: 165
Phone: 16179265000
EYEPOINT PHARMACEUTICALS INC / EYPT FAQ
What does EYEPOINT PHARMACEUTICALS INC do?
EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. The company is headquartered in Watertown, Massachusetts and currently employs 165 full-time employees. The company went IPO on 2005-01-27. The firm is focused on developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E. DURAVYU is presently in Phase 3 global, pivotal clinical trials for wet age-related macular degeneration (wet AMD). Additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The Company’s other products include YUTIQ and DEXYCU.
What is the current price of EYPT stock?
The current stock price of EYPT is 11.99 USD. The price increased by 2.96% in the last trading session.
Does EYPT stock pay dividends?
EYPT does not pay a dividend.
What is the ChartMill technical and fundamental rating of EYPT stock?
EYPT has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Which stock exchange lists EYPT stock?
EYPT stock is listed on the Nasdaq exchange.
Can you provide the PE ratio for EYPT stock?
EYEPOINT PHARMACEUTICALS INC (EYPT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.99).
Can you provide the growth outlook for EYEPOINT PHARMACEUTICALS INC?
The Revenue of EYEPOINT PHARMACEUTICALS INC (EYPT) is expected to decline by -14.15% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
EYPT Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to EYPT. When comparing the yearly performance of all stocks, EYPT is one of the better performing stocks in the market, outperforming 81.84% of all stocks.
EYPT Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to EYPT. While EYPT has a great health rating, there are worries on its profitability.
EYPT Financial Highlights
Over the last trailing twelve months EYPT reported a non-GAAP Earnings per Share(EPS) of -2.99. The EPS decreased by -49.5% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -81.75% | ||
| ROE | -102.78% | ||
| Debt/Equity | 0 |
EYPT Forecast & Estimates
19 analysts have analysed EYPT and the average price target is 35.1 USD. This implies a price increase of 192.79% is expected in the next year compared to the current price of 11.99.
For the next year, analysts expect an EPS growth of -34.72% and a revenue growth -14.15% for EYPT